Bair, S. M., Strelec, L. E., Feldman, T. A., Ahmed, G., Armand, P., Shah, N. N., Singavi, A. N., Reddy, N., Khan, N., Andreadis, C., Vu, K., Huntington, S. F., Giri, S., Ujjani, C., Howlett, C., Faheem, M., Youngman, M. R., Nasta, S. D., Landsburg, D. J., Schuster, S. J., & Svoboda, J. (2019). outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis. Oncologist, 24, 955–962. http://access.bl.uk/ark:/81055/vdc_100088877447.0x000059